IL1A and neoplasm: Altogether, we believe we have identified a combined high nuclear IL-1α/EGFR+ tumor expression profile as a strong prognostic biomarker for progression-free survival in OSCC patients which warrants further study in other HNSCCs and other EGFR-expressing tumors.